Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVA-BN vaccine in children and adults for smallpox, mpox, and orthopoxvirus prevention
NCT06549530Phase 2Active, not recruiting
- Sponsor
- Bavarian Nordic
- Start
- Oct 2024
- Primary completion
- May 2026
- Modality
- Live Attenuated Vaccines
- Countries
- 2
01
Overview
A Phase 2 trial of JYNNEOS in smallpox, mpox, Orthopoxvirus infections, sponsored by Bavarian Nordic. Started Oct 2024; status: active, not recruiting.
02
Drugs
JYNNEOS
03
Conditions
smallpoxmpoxOrthopoxvirus infections
Beyond the preview
Go deeper on NCT06549530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06549530.